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Abstract: Background: Hepatocellular carcinoma (HCC) results in
more than 600,000 deaths per year. Transarterial embolisation
(TAE) and transarterial chemoembolisation (TACE) have become
standard loco-regional treatments for unresectable HCC.
Objectives: To assess the beneﬁcial and harmful effects of TACE or
TAE.
Search strategy: We searched The Cochrane Hepato-Biliary Group
Controlled Trials Register, The Cochrane Cancer Network register,
The Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library, MEDLINE, EMBASE, Science Citation Index
Expanded, and The Latin American Caribbean Health Sciences Liter-
ature (LILACS) from dates of inceptions up to September 2010.
Selection criteria: We considered for inclusion all randomised trials
that compared TACE or TAE versus placebo, sham, or no intervention.
Co-interventions were allowed if comparable between intervention
groups. Trials with inadequate randomisation were excluded.
Data collection and analysis: For all-cause mortality, we calcu-
lated the log hazard ratio (HR) with standard error as point estimate
and pooled them for meta-analysis using the inverse variance
method. Sub-group analyses were performed regarding intervention
regimen, trial truncation, or co-interventions. We validated the
results with trial sequential analyses. We used random-effects model
in all meta-analyses in anticipation of statistical heterogeneity
among the trials.
Main results: We included nine trials with 645 participants. Six tri-
als assessed TACE versus control and three trials assessed TAE versus
control. Seven trials had low risk of selection bias based on adequate
generation of allocation sequence and concealment – but all theseJournal of Hepatology 20
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tality, statistical heterogeneity between trials was low to moderate
(I2) = 30%). Meta-analysis of trials with low risk of selection bias
showed that TACE or TAE versus control does not signiﬁcantly
increase survival (HR 0.88; 95% CI 0.71–1.10). Two trials with low
risk of selection bias, no early stopping, and no co-intervention did
not establish any signiﬁcant effect of TACE or TAE on overall survival
(hazard ratio 1.22, 95% conﬁdence interval 0.82–1.83; P = 0.33). Trial
sequential analysis conﬁrmed the absence of evidence for a beneﬁcial
effect of TACE or TAE on survival indicating the need for future ran-
domisation of up to 383 additional participants. Substantial differ-
ences in criteria for assessing tumor response did not allow
quantitative analyses. One trial investigated quality of life but did
not detect any signiﬁcant differences between the intervention
groups. A range of adverse events including post-embolisation syn-
drome and serious complications were reported.
Authors’ conclusions: There is no ﬁrm evidence to support or refute
TACE or TAE for patients with unresectable HCC. More adequately
powered and bias-protected trials are needed.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Hepatocellular carcinoma is an orphan disease in terms of scien-
tiﬁc evidence. Only few randomized controlled trials (RCT) or
meta-analysis of individual data have been conducted, none of
them including more than 1000 patients. In addition, most of
the widely accepted treatments with impact on survival such as
surgical resection, liver transplantation, and local ablation are
supported by cohort analysis, categorized as low-medium level
of evidence according to the main categories of evidence-based
medicine [1]. Only two treatments options in HCC have proven
their impact on survival at a higher level of evidence by positive
RCTs: transarterial chemoembolization (TACE) for intermediate
HCC and sorafenib for advanced HCC [2]. The demonstration of
efﬁcacy of TACE was reinforced in 2002 at the time of the publi-
cation of two positive RCT after previous trials with discordant
results [3,4]. Two meta-analysis of pooled data published after-
wards established the value of TACE in this scenario [5,6] and this
assessment became the background for accepting TACE as the12 vol. 56 j 984–986
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primary standard of care option for intermediate HCC as deﬁned
by the BCLC staging system [2]. Oliveri et al. questioned the
robustness of the scientiﬁc evidence supporting the use of TACE
and run a new systematic review and meta-analysis including
novel RCTs conducted beyond 2002 using the methodology pro-
posed by the Cochrane collaboration. According to the reported
results, the authors concluded that there is no ﬁrm evidence to
support or refute TACE or TAE for patients with unresectable
HCC, calling for more adequately powered and bias-protected tri-
als to conﬁrm the utility of these treatments in this scenario [7].
The message delivered by this Cochrane review is relevant as
it casts doubts about the usefulness of TACE for HCC. However,
there are several aspects that need to be considered regarding
the studies used and the methodology applied to deﬁne their
quality and their incorporation into the assessment. Firstly, the
authors justiﬁed the need of a new meta-analysis because of
the publication of additional RCTs after 2002. In one of these
studies, categorized as high risk of bias by Oliveri et al., the
authors evaluated the combination of transarterial embolization
(TAE) + ablation versus ablation alone in patients with solitary
tumors, most of them belonging to the early stage category. In
this RCT, the hypothesis was that TAE + percutaneous ablation
could be superior to the standard treatment (in this case ethanol
injection or radiofrequency) for early non-resectable HCCs. Thus,
they do not investigate TACE compared to best supportive care or
suboptimal therapies, as expected for consistency in this meta-
analysis. In addition, they failed to include the target population
for this therapy, meaning patients with intermediate HCC [8]. The
second paper was published by Doffoël et al. in 2008 [9]. In this
study, 138 patients were recruited from 15 centers during an
inclusion time of around 7 years. The study included a high pro-
portion of alcoholic-induced HCC patients and with segmental
vascular invasion. Stratiﬁcation was based upon Child-Pugh and
Okuda stage, which do not provide major insights about tumor
stage as per today’s knowledge. Median survival was 12 months
for TACE patients and 11 months for those treated with tamoxi-
fen. Outcome ﬁgures expected during the years that the study
was conducted points to a median survival for the active arm of
20 months. Therefore, our hypothesis to understand these cer-
tainly low survival rates according to standards for effective TACE
was that patients were sub-optimally staged, selected and/or
treated. In fact, most of the patients were symptomatic and
would ﬁt into BCLC C -advanced stage- and hence they would
no longer be considered ideal candidates for TACE as per current
guidelines. In addition, the large number of centers and long time
period needed to conduct this trial suggest that the participant
centers were not referral institutions with a high volume/exper-
tise. The same concerns about selection and treatment applica-
tion affects the Pelletier et al. study in 1990 [10]. This study
was discarded in two previous meta-analyses [5,6] because the
authors only reported 1-year survival rates, which indeed was
unacceptably low and prone to induce bias. It is worth mention-
ing that in this trial the obstructing agent used was gelfoam pow-
der that has been abandoned because of known risk of biliary
damage and severe treatment-related complications [11].
Therefore, by including trials not targeting the proper popula-
tion and treatment strategy, and trials including patients that do
not ﬁt into the accepted proﬁle for TACE, the meta-analysis
turned negative. The stratiﬁcation into different subgroups
according to bias or other criteria prevented to reach the needed
strength of the data as the sample size is clearly suboptimal,Journal of Hepatology 201while the low-proﬁle trials were still used. Finally, when willing
to estimate the sample size that would be required for robust
assessment, it appears that Oliveri et al. have used a very modest
expectation in survival improvement: 10%. The background ratio-
nale for this assumption is not available and sure this is one of the
controversial issues for which there is no solid data.
According to their ﬁndings, Oliveri et al. state that there is an
urgent need of more adequately powered and bias-protected tri-
als to conﬁrm the utility of these treatments in this scenario.
Additional trials with proper design and target population would
be welcome, but attempts in this direction failed to recruit in
United Kingdom. A trial comparing TACE vs. systemic doxorubicin
was launched time ago (PI: OJ Garden, NCT00079027) but it was
prematurely closed because of insufﬁcient recruitment.
While years ago there were major discrepancies and heteroge-
neity in patients’ selection and treatment application, the current
situation is far more structured. The optimal population for TACE
has been identiﬁed (namely BCLC B patients with compensated
liver disease) and the technique application has been improved.
Hence, information collected from studies in which current
knowledge is not followed does not provide further knowledge
but rather trigger more confusion. The current status about indi-
cation of TACE, its application and how retreatment policy should
be implemented has been recently summarized by a panel of
experts [12].
All these comments serve to frame the limitations of the Oli-
veri’s meta-analysis and why it may provide a vulnerable mes-
sage that would bring the controversy back to where it was a
decade ago. Efforts should be directed at avoiding the misuse of
an effective treatment and to further improve its effectiveness.
Several areas of uncertainty exist: which is the best embolic
agent, which the best chemotherapeutic, what is the best fol-
low-up and retreatment policy (repeat treatment according to a
ﬁxed schedule or upon disease progression after initial response)
and to which extent we could develop combined therapies. Trials
are ongoing in this direction and hopefully will result in an exten-
sion of the survival beneﬁts of an effective approach if applied as
recommended.Conﬂict of interest
J.L. is consultant for Biocompatibles.
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